Literature DB >> 2943748

Functional differences in the interactions of glycosylation-deficient cell lines with fibronectin, laminin, and type IV collagen.

R C Hughes, G Mills.   

Abstract

Fibronectin isolated from the conditioned medium of monolayer cultures of baby hamster kidney (BHK) cells and several ricin-resistant (Ric) mutants derived from them express differences in N-glycosylation. The asparagine-linked oligosaccharides of BHK cell-derived fibronectin consist largely of complex chains, whereas hybrid and/or high-mannose chains are present in the fibronectins of mutant cell lines. The fibronectins exhibiting different glycosylation patterns are incorporated to similar extents into the cell-layer of human skin fibroblasts. In contrast, mutant cells retain significantly less endogenously produced fibronectin than BHK cells and also incorporate less human cellular fibronectin into a pericellular matrix. In vitro adhesion assays show that mutant cells attach to and spread relatively poorly on fibronectin-or type IV collagen-coated substrata but interact as well as do BHK cells with a laminin substratum. These results indicate that asparagine-linked oligosaccharides of fibronectin are not required for the binding and incorporation of the molecule into cell layers, but, as constituents of other cellular glycoproteins, they do modulate the ability of BHK cells to interact with some matrix components.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2943748     DOI: 10.1002/jcp.1041280309

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  1 in total

1.  Mannosidase 2, alpha 1 deficiency is associated with ricin resistance in embryonic stem (ES) cells.

Authors:  Wei Wang; Christine Hale; Dave Goulding; Stuart M Haslam; Bérangère Tissot; Christopher Lindsay; Stephen Michell; Rick Titball; Jun Yu; Ana Luisa Toribio; Raffaella Rossi; Anne Dell; Allan Bradley; Gordon Dougan
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.